Tat-Based Therapies as an Adjuvant for an HIV-1 Functional Cure

Hongping Jin,Dongsheng Li,Min-Hsuan Lin,Li Li,David Harrich

DOI: https://doi.org/10.3390/v12040415

2020-04-08

Viruses

Abstract:The human immunodeficiency virus type 1 (HIV) establishes a chronic infection that can be well controlled, but not cured, by combined antiretroviral therapy (cART). Interventions have been explored to accomplish a functional cure, meaning that a patient remains infected but HIV is undetectable in the blood, with the aim of allowing patients to live without cART. Tat, the viral transactivator of transcription protein, plays a critical role in controlling HIV transcription, latency, and viral rebound following the interruption of cART treatment. Therefore, a logical approach for controlling HIV would be to block Tat. Tackling Tat with inhibitors has been a difficult task, but some recent discoveries hold promise. Two anti-HIV proteins, Nullbasic (a mutant of Tat) and HT1 (a fusion of HEXIM1 and Tat functional domains) inhibit viral transcription by interfering with the interaction of Tat and cellular factors. Two small molecules, didehydro-cortistatin A (dCA) and triptolide, inhibit Tat by different mechanisms: dCA through direct binding and triptolide through enhanced proteasomal degradation. Finally, two Tat-based vaccines under development elicit Tat-neutralizing antibodies. These vaccines have increased the levels of CD4+ cells and reduced viral loads in HIV-infected people, suggesting that the new vaccines are therapeutic. This review summarizes recent developments of anti-Tat agents and how they could contribute to a functional cure for HIV.

What problem does this paper attempt to address?

This paper aims to explore the possibility of achieving a functional cure for HIV - 1 by using Tat protein as an adjuvant therapy. Specifically, the paper focuses on controlling HIV transcription by blocking the function of Tat protein, thereby achieving the purpose of suppressing viral replication. The Tat protein plays a key role in the transcriptional regulation of HIV, being able to activate the expression of viral genes, maintain the latent state of the virus, and cause viral rebound. Therefore, the development of effective inhibitors or vaccines against Tat is of great significance for achieving a functional cure for HIV.

The main research directions mentioned in the paper include:
1. **Transcriptional activation mechanism of Tat**: Tat promotes the efficient transcription of HIV by interacting with host cell factors, especially by binding to the P - TEFb complex.
2. **Inhibitors of Tat**: The paper discusses several inhibitors against Tat, such as Nullbasic (a mutated Tat protein), HT1 (a fusion protein of HEXIM1 and Tat functional domains), didehydro - cortistatin A (dCA) and triptolide. These inhibitors block the function of Tat through different mechanisms, thereby inhibiting HIV transcription and replication.
3. **Tat vaccines**: The paper also introduces two Tat vaccines under development, namely Tat - BH10 and Tat - Oyi. These vaccines can induce the production of neutralizing antibodies against Tat, increase CD4+ T - cell levels, and reduce viral load, showing therapeutic potential.

In conclusion, the problem that this paper attempts to solve is how to develop effective treatment methods by targeting the Tat protein to achieve a functional cure for HIV - 1.